COVID-19 Vaccine AstraZeneca Data
Adjusted To 76% Effective 
AstraZeneca has released updated data on its COVID-19 vaccine, claiming that more recent
review shows the vaccine to be 76% effective against symptomatic COVID-19. That's a slight
drop in affinity to the 79% the company touted in an announcement earlier this week. That figure
was based on outdated data, US health officials said in an unusual public statement berating the
company.
Initial efficacy was based on an intermediate break down using data collected up to February
17. But the addition of more data collected after that date showed the vaccine could have been
69-74% effective, according to a letter from the independent committee overseeing the clinical
trial and reported by the Washington Post. The committee "strongly recommended" that these
figures be included as well.
The new result is a few higher percentage focuses, but a finding in that range would still have
been a good result and much higher than the half-point effectiveness threshold that the US
Food and Drug Administration said it wanted. COVID-19 vaccines last fall. A federal official told
the Washington Post that AstraZeneca's decision to publish only the most number this week
was as "important to your mother that you got an A in a course, when you got an A in the
course. head test, but a C throughout the course.
"Thedistribution of scientific information in a news dispatch rather than in a scientific paper
means that external specialists can not Analyst allegations. Originally Companies first three
Covid-19 vaccines licensed in the United States also announced for the first time the results of
their clinical trials in press reports. Their data held up, but scholars have always criticized this
strategy. AstraZeneca's botched data distribution shows why they were so cautious.
The updated data indicate that, more than likely, this vaccine is a good vaccine and that it
emanates a major role to play in the global fight against COVID-19. It is inexpensive standard
compatibility with Moderna and Pfizer / BioNTech vaccines, it can be stored at room temperature
and it has been designated as the head vaccine for immunizing low income countries.
But over the past year it has been more defined by controversy than by good science. The
company was not transparent with regulators when the trial had safety concerns, for example,
and its clinical trial had errors and hazy methodology. The American clinical trial was supposed
to dispel the disarray. Instead, the botched data distribution has added to the mess as public
health officials attempt to build confidence in COVID-19 vaccines.
Commentaires
Enregistrer un commentaire